Short answer
Voyager Therapeutics, Inc. (VYGR) filed an 8-K current report with the SEC on June 10, 2026 reporting Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 5.07 (Submission of Matters to a Vote of Security Holders). Authorized capital stock doubled from 125M to 245M shares.
Voyager Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- Authorized capital stock doubled from 125M to 245M shares
- Authorized common stock doubled from 120M to 240M shares
- Amendment effective June 9, 2026, following stockholder approval and Delaware filing
- Expanded share capacity supports potential financings, acquisitions, equity compensation, or dilution risk
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Three Class II directors elected through 2029, preserving board continuity
- Executive compensation advisory proposal approved, with 32,041,373 votes for
- Ernst & Young LLP ratified as independent auditor for fiscal 2026, with 45,902,883 votes for
- Authorized capital increased from 125,000,000 to 245,000,000 shares
- Common-stock authorization doubled from 120,000,000 to 240,000,000 shares, enabling future issuance and dilution risk
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Voyager Therapeutics, Inc. 8-K filings
Get the next VYGR 8-K as it lands
Follow VYGR for push alerts, or ask the research agent what this filing means.